Company / Operating Cash Flow
Immuneering Corp Operating Cash Flow History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$44.1M
FY2023
5-year range
-$44.1M / -$14.6M
FY2021-FY2023
Trend
-42.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$15M to -$44M over the past 2 years.
Based on SEC 10-K filings.
-$44M in FY2023.
Declined from -$15M to -$44M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, operating cash flow decreased 42.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$44.1M | -42.9% |
| FY2022 | -$30.9M | -111.0% |
| FY2021 | -$14.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026